1. Scrip
  2. >>Conferences

What Late-Breakers To Look Out For At ASCO 2019

 
• By Alexandra Shimmings

Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.

Stage
Setting the Stage for ASCO 2019 • Source: Shutterstock

ASCO drew back the curtain on 15 May on what to expect at its annual meeting later this month, providing a sneak peek as to what will be presented during its late-breaking sessions. Drawing on a ASCO preview report from Pharma Intelligence’s Biomedtracker and Datamonitor Healthcare, here is a look at the most notable studies for the industry that will be in the spotlight at the Chicago meeting from 31 May to 4 June.

Just how effective AstraZeneca PLC/Merck & Co. Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

More from Conferences